1. Product advantages

♦ High purity, all above 98.5%, no impurities after dissolution

♦ We will test each batch to ensure quality

♦ OEM and private brand services designed for free

♦ Various cap colors available

♦ We can also provide MT1 peptide powder

2. Factory advantages

♦ Professional research team

♦ More than 5 doctors in high-tech R&D laboratories

♦ More than 1000 m2 of factory production line to ensure stable supply

♦ More than 1200 factories to manufacture products and control quality

3. Service advantages

♦ 24-hour online service

♦ Track package information and update it for customers

♦ Professional sales team

♦ Accept small order service

♦ Redelivery service if detained by customs

Metformin (1, 1-dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leads to AMPK activation, and enhances insulin sensitivity, which can be used in the study of type 2 diabetes. Metformin can penetrate the blood-brain barrier and induce autophagy. Density 1.0743

Boiling point 229.23°C

Melting point: 199-200 °C

Molecular formula C4H11N5

Molecular weight 129.164

The flash point is 58.1±22.6 °C

Exact mass 129.101440

PSA 88.99000

LogP minus 2.31

Appearance: Solid,White to Light Brown

The vapor pressure was 1.3±0.3 mmHg at 25°C

The refractive index is 1.576

Aqueous solubility (Slightly), Aqueous Acid (Slightly), Dichloromethane (Slightly), DM

For mild diabetes. It is mainly used for non-insulin dependent diabetes mellitus, which can be used as the first choice for obese patients, and can also be used in combination with insulin for insulin dependent diabetes mellitus. It is effective in some cases where sulfonylurea is not effective.

This product is a kind of biguanide oral hypoglycemic drugs. It has a variety of mechanisms of action, including delaying glucose uptake by the gastrointestinal tract, increasing peripheral glucose utilization by improving insulin sensitivity, and inhibiting excessive gluconeogenesis in the liver and kidney. This product does not lower blood glucose levels in non-diabetic patients. Weight loss, reduction in plasma cholesterol, triglycerides, and probeta-lipoprotein levels, and improvement in peripheral glucose metabolism are usually observed during treatment.

Hypoglycemic effect

The hypoglycemic effect of this product is accurate, and there is no hypoglycemic reaction compared with sulfonylureas. It is effective in both obese and non-obese patients with non-insulin dependent diabetes mellitus (NIDDM). For those who are ineffective in diet therapy alone, this product can reduce the basal blood glucose concentration by ≥20%(generally 2mmol/L or 36mg/dl). It can improve oral or intravenous glucose tolerance test, and its hypoglycemic effect is independent of the blood glucose concentration before medication, age, course of disease, weight and basal insulin level. It is often used in combination with sulfonylurea in patients who are not satisfied with the control of sulfonylurea alone, which can reduce the blood glucose by more than 20% than that of sulfonylurea alone, and can reduce the amount of insulin when combined with insulin.

Mechanism of lowering glucose

① The hypoglycemic mechanism of this product is different from that of sulfonylureas, it does not stimulate insulin secretion, and its hypoglycemic effect is mainly to increase the anaerobic glycolysis of sugar in the surrounding tissues and increase the utilization of sugar. The main part of this effect is in the small intestine. Animal tests have shown that this product can increase the anaerobic glycolysis of the small intestine and increase the utilization of sugar in the jejunum by 20%.

② Inhibition of hepatic gluconeogenesis, and reduction of basal glucose output due to reduction of gluconeogenesis secondary to basal glucose reduction. ③ By increasing the binding of insulin and insulin receptor, increase the clearance effect of insulin on blood glucose. As insulin resistance is a characteristic of NIDDM, this product can improve the sensitivity of NIDDM patients to insulin by increasing the number of receptor binding sites and increasing the number of low affinity binding sites. Animal studies have demonstrated that the product also has a post-receptor effect, increasing insulin-stimulated glycogen production, increasing insulin receptor phosphorylation and increasing tyrosine kinase activity.